

# Gilead HIV Pipeline

## Legend

PHASE 1 PHASE 2 PHASE 3 PHASE 4

### Clinical Program

### Modality

### Phase

#### HIV Prevention

Lenacapavir (PURPOSE 365)

PrEP LAI



#### HIV Treatment

Bictegravir/lenacapavir oral combination (ARTISTRY-1 & ARTISTRY-2)<sup>1</sup>

HIV Oral



Islatravir/lenacapavir oral combination (ISLEND-1 & ISLEND-2)<sup>2</sup>

LAO



HIV capsid inhibitor (GS-3107)

LAO



Lenacapavir + teropavimab + znlirvimab<sup>3</sup>

LAI



HIV INSTI (GS-1219)

LAI



HIV NRTTI (GS-3242)

LAI



#### HIV Cure

Teropavimab + znlirvimab<sup>3,4</sup>

Cure



Vesatolimod (FRESH)

Cure



HIV bispecific T-cell engager (GS-8588)

Cure



As reported in Gilead's Q1 2026 Earnings Statement.

[https://www.gilead.com/sfhence/pipeline#pipeline\\_pipeline%20tags=HIV%20Treatment%7C%7CHM%20Prevention%7C%7CHM%20Cure](https://www.gilead.com/sfhence/pipeline#pipeline_pipeline%20tags=HIV%20Treatment%7C%7CHM%20Prevention%7C%7CHM%20Cure)



Pipeline shown above as of May 1, 2026. 1. Filed. NDA Submitted. 2. Subject to Gilead and Merck co-development and co-commercialization agreement. 3. Teropavimab and znlirvimab are broadly neutralizing antibody (bNAbs). 4. Non-Gilead sponsored trial(s) ongoing. HM - human immunodeficiency virus, INSTI - integrase strand transfer inhibitor, NRTTI - nucleoside reverse transcriptase translocation inhibitor, LAI - long-acting injectable, LAO - long-acting oral, PrEP - pre-exposure prophylaxis.

Date of approval, May 2026. GFM-UNB-2512